Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to Issue Quarterly Dividend of $0.88

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) declared a quarterly dividend on Tuesday, February 4th,RTT News reports. Shareholders of record on Thursday, February 20th will be paid a dividend of 0.88 per share by the biopharmaceutical company on Thursday, March 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.49%.

Regeneron Pharmaceuticals Trading Up 3.9 %

Regeneron Pharmaceuticals stock opened at $724.23 on Wednesday. Regeneron Pharmaceuticals has a 1 year low of $642.00 and a 1 year high of $1,211.20. The firm’s 50 day moving average price is $718.04 and its two-hundred day moving average price is $916.32. The firm has a market cap of $79.59 billion, a price-to-earnings ratio of 17.96, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $11.86 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals will post 37.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

REGN has been the topic of a number of recent analyst reports. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Bernstein Bank reduced their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Finally, Evercore ISI reduced their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $982.43.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.